Cent, a preventive health intelligence company, has raised $15 million in a Series A funding round comprising equity and debt, co-led by Blume Ventures and existing investor South Park Commons (SPC). The company will use the capital to strengthen its research and development capabilities, expand its artificial intelligence and clinical teams, and build an integrated preventive healthcare platform for India.

The round also attracted individual investors, including Arun Sarin, former CEO of Vodafone; Srinivas Narayanan, former CTO (B2B) at OpenAI; Sharath Narayana; Krishna Sridhar; and Aprameya Radhakrishna.

Founded in 2025, Cent is building a vertically integrated preventive health platform combining purpose-built hardware, AI-driven radiology and diagnostics, and bioinformatics. The company aims to identify potential health risks and serious diseases before symptoms appear, while enabling individuals to track their health over time.

Since its inception, Cent has completed 10,000 preventive whole-body scans across Bengaluru, Mumbai and Delhi. It has also acquired Medsee, an AI-powered radiology reporting platform, as it looks to strengthen its diagnostic capabilities and support higher scan volumes. The company has set a target of completing 10 million scans by 2035.

Building a Preventive Healthcare Model

Cent was founded by Shashank ND, founder of Practo and OneFlow Holdings; Anshul Khandelwal, former Chief Marketing Officer of Ola Electric; and Arpit Garg, former product head at Lenskart.

The founders established the company around a gap they identified in India’s healthcare system: serious conditions such as cardiovascular disease, cancer and metabolic disorders are often detected only after symptoms emerge, when treatment can become more complicated.

Cent aims to shift the focus from treating illness after its onset to identifying potential health concerns earlier. Its approach combines medical imaging, diagnostic testing and AI-driven analysis to bring different health indicators into a consolidated picture.

The company is developing its platform across three key areas: purpose-built hardware, clinical intelligence and consumer-facing preventive health services. By integrating these capabilities, it intends to build a system that supports early detection, personalised health assessments and longitudinal tracking of an individual’s health.

The newly raised funding will support further research and development, particularly in AI, medical imaging and clinical research, alongside expansion of the company’s engineering and clinical teams.

Investors Back Early Detection and Healthcare Infrastructure

Blume Ventures and South Park Commons have backed Cent’s ambition to develop preventive healthcare infrastructure that can serve a wider population.

Karthik Reddy, Co-founder and Managing Partner at Blume Ventures, said the team demonstrated a strong commitment to improving diagnostic accuracy and developing protocols for cancer and other medical conditions.

He added that the firm’s investment reflected its longstanding conviction in health technology and its belief that Cent could eventually extend its model beyond India.

Prateek Mehta, General Partner at South Park Commons India, highlighted the importance of early detection in identifying potentially serious health conditions.

“With every scan, Cent has shown that early detection changes lives. Behind every one of those scans is a family that otherwise wouldn’t have known what was wrong. We’re proud to partner with the team as they build preventive health infrastructure India can rely on,” Mehta said.

He added that the company was addressing the need to identify conditions such as tumours and blocked arteries before they become more serious.

Anshul Khandelwal, Co-founder of Cent, said the company believes preventive care must become more precise and accessible as India’s healthcare system evolves.

“India’s healthcare system is still built to treat illness, not to find it early. We believe the next shift is preventive care that is precise and accessible at scale. Our first 10,000 scans have shown us how much that shift is needed,” Khandelwal said.

He added that the funding would enable the company to deepen its work in AI, medical imaging and clinical research while building preventive healthcare infrastructure in India with potential applications in international markets.

Medsee Acquisition to Strengthen AI Radiology Capabilities

Alongside the funding announcement, Cent has acquired Medsee, an AI-powered radiology reporting workflow platform founded by Chitra Singh.

Medsee is designed for use by qualified medical professionals. Its technology drafts structured radiology reports and highlights findings for review by radiologists, with the objective of making reporting faster and more consistent.

The acquisition is expected to strengthen Cent’s radiology workflow as the company expands its scanning operations.

Medical imaging generates substantial volumes of information that require careful interpretation by trained professionals. AI-assisted reporting tools can help organise findings and support clinical workflows, although medical decisions and final interpretations remain dependent on qualified healthcare professionals.

For Cent, integrating Medsee into its broader platform could help support operational efficiency while maintaining specialist oversight as scan volumes increase.

Cent Check Combines Imaging and Diagnostic Assessments

Cent’s flagship service, Cent Check, brings together multiple diagnostic procedures in a single visit lasting approximately two hours.

The assessment includes full-body magnetic resonance imaging (MRI), low-dose computed tomography (CT), dual-energy X-ray absorptiometry (DEXA), electrocardiography (ECG), echocardiography (ECHO) and more than 100 biomarkers under the company’s proprietary CCNM™ Protocol.

Cent’s AI systems consolidate the results into an integrated health assessment, after which specialist doctors review the findings. Members receive a doctor-led plan and support throughout the year.

According to the company, among members who felt well when they arrived for screening, one in four had a finding considered worth acting on, while one in 40 required immediate medical attention. The company cited examples including early-stage tumours, significantly narrowed arteries and aneurysms.

These figures reflect Cent’s reported experience among its screened members. They should not be interpreted as population-wide estimates, as findings can vary depending on the individuals screened, their risk profiles and the protocols used.

The company’s approach is designed to identify potential health concerns that may not be apparent from symptoms alone. Any screening finding requiring further investigation or treatment must be assessed by qualified medical professionals.

Building a Health Dataset for Indian Populations

Cent’s preventive health model also generates data that could support research into health patterns among people who do not present with obvious symptoms.

The company plans to use information gathered through its scans to develop Indian population-specific baselines for health indicators, train models to identify disease risks earlier and support clinical research.

The objective is to improve the relevance of preventive assessments by building a stronger understanding of health patterns within Indian populations.

Developing reliable predictive models, however, requires robust clinical validation, appropriate data governance and careful assessment of model performance across different population groups. The usefulness of such models will depend on the quality of the underlying data and their ability to support meaningful clinical decisions.

As Cent expands, the data generated through its operations could become an important component of its research and product development strategy.

Targeting 10 Million Scans by 2035

With 10,000 scans completed since inception, Cent is now targeting 10 million scans by 2035. Reaching that milestone would require substantial expansion of its operational capacity, clinical teams, technology infrastructure and access to preventive screening services.

The company’s current centres operate across Bengaluru, Mumbai and Delhi NCR. Its next phase will focus on strengthening its technology platform, expanding AI and clinical capabilities, and improving the systems required to manage increasing volumes of diagnostic information.

The acquisition of Medsee adds another component to this strategy by supporting AI-assisted radiology workflows as the business scales.

Cent’s longer-term ambition is to build an integrated preventive health platform that combines diagnostics, medical imaging, AI and longitudinal health monitoring.

Conclusion

Cent’s $15 million Series A funding marks a new phase in its effort to build preventive healthcare infrastructure in India. Backed by Blume Ventures, South Park Commons and individual investors, the company plans to invest in AI, medical imaging, clinical research and team expansion.

Its acquisition of Medsee adds AI-assisted radiology reporting capabilities, while its target of 10 million scans by 2035 reflects an ambition to expand preventive screening at scale.

The company’s progress will depend on its ability to expand access, maintain clinical quality and demonstrate the effectiveness of its screening and predictive technologies. As preventive healthcare gains attention, Cent is positioning itself around a model that combines diagnostic infrastructure, technology and specialist medical oversight to identify potential health risks earlier.

By : Vanshika Tayal